First Flight Venture Center

AthemBio is a biotechnology company focused on addressing significant challenges in biologics manufacturing through innovative technologies. The company specializes in developing advanced medical devices and bioprocessing systems designed to isolate and purify therapeutic antibodies. These solutions aim to enhance the treatment of COVID-19 and other infectious diseases, ultimately contributing to the fight against pandemics and emerging pathogens. AthemBio's commitment to creating effective bioprocessing solutions positions it as a key player in the healthcare sector.

Regennova is a biotechnology company dedicated to developing innovative therapies for inflammatory diseases and neurological disorders. The company's focus includes conditions such as cerebral stroke, traumatic brain injury, and Alzheimer's disease, as well as addressing challenges related to sepsis and septic shock, particularly in the context of multi-drug resistant bacteria. Through its research and development efforts, Regennova aims to provide effective treatments for conditions associated with tau-mediated diseases, thereby improving patient outcomes in these critical areas of healthcare.

Akanocure Pharmaceuticals is a biotechnology company focused on developing innovative anti-cancer chemotherapeutic drugs aimed at treating various forms of cancer. The company is dedicated to finding therapeutic approaches that effectively block the metastatic processes responsible for 90% of cancer-related deaths. By harnessing the expertise of its team throughout the drug discovery and development phases, Akanocure aims to create novel small molecules derived from natural resources. These bio-targeted therapeutics are designed not only to combat cancer but also to alleviate the side effects associated with chemotherapy and other cancer treatments, ultimately improving the quality of life for patients.

Operator of a cell-based biotechnology platform designed to produce messenger ribonucleic acid(mRNA) therapeutics and vaccines. The company's platform uses cell engineering, computational biology, and precision fermentation to optimize the production of vaccinia capping enzymes, enabling medical professionals to provide optimal medicines to their patients.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

QUANTiSCOPE improves drug discovery by providing automated image analysis tools that are simple to integrate into research processes.

Avecris specializes in genetic medicine through its advanced genetic vector platform, which enhances mRNA and RNA applications. The company offers a range of services, including stable and long-lasting protein expression, cell-type specific gene expression, and a unique ability to deliver mitochondrial gene therapy. Its non-integrating approach minimizes the risk of eliciting innate immunity, while also allowing for redosable and titratable treatments. The platform utilizes a DNA-based backbone construct that is universal and unmodified, featuring a modular coding region for rapid and flexible application development. Additionally, Avecris is committed to efficient manufacturing processes that are scalable and cost-effective, ensuring that clients can access tailored therapeutic proteins to meet their specific needs.

Qatch Technologies is focused on creating innovative tools to assess the injectability and manufacturability of biopharmaceutical products. The company has developed a proprietary pre-screening technology that integrates microfluidics and acoustics, allowing for the precise measurement of viscosity using minimal liquid volumes. This advanced technology enables biopharmaceutical researchers to identify suitable injectable formulations at early stages of development, thereby streamlining the process of selecting optimal molecules for further study. By addressing potential manufacturing challenges related to viscosity, Qatch Technologies aims to enhance the efficiency and effectiveness of drug development in the biopharmaceutical sector.

Jurata Thin Film specializes in innovative storage technology for vaccines and biologics, aimed at enhancing their manufacturing, distribution, and delivery processes. The company has developed a unique thermostable film matrix that stabilizes biological materials, including bacterial-based vaccines and antibody-based therapeutics, allowing them to retain therapeutic efficacy even under extreme temperature conditions. This technology facilitates the long-term storage of vaccines and biologics at room temperature or higher, significantly simplifying logistics and accessibility. Additionally, the therapeutic cargo stored within this film can be rehydrated to recover the payload in an aqueous solution, offering versatile delivery options for healthcare providers.

PrecNA is a manufacturer of customised lipid nanoparticle formulation equipment.